BC-CfE urges heightened caution due to monkeypox

Health authorities in Canada, the US, Spain, Portugal, and the UK have issued alerts over possible outbreaks of monkeypox. This viral infection is usually spread by respiratory transmission, but in these latest cases certain characteristics point towards fluid contact as a possible mode of transmission. A majority of these monkeypox cases are among men who have sex with men.

Read More »

BC-CfE researchers examine HCV knowledge and awareness of reinfection risk among people successfully treated with direct acting antiviral therapy

The Hepatitis C virus (HCV) is a blood borne infection and a leading cause of end-stage liver disease. The World Health Organization estimates that about 58 million people are living with chronic HCV, leading to 290,000 deaths annually due to HCV-related liver illness. Here in Canada, HCV affects a quarter of a million people. Of this quarter million, over 40% are unaware of their infection.

Read More »

BC-CfE study examines how neighbourhood poverty affects those living with HIV

A recently published study by BC-CfE researchers titled Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort studyexamines the relationship between a neighbourhood’s socioeconomic status and how this affects the lives and health of Canadians living with HIV who are on combination antiretroviral therapy (ART).

Read More »

HIV cure research advanced with deeper knowledge of viremic controllers

There is currently no cure for HIV because the virus is able to persist in the body even during long-term antiretroviral therapy. BC-CfE scientists have published new research that characterizes in detail the HIV sequences that persist in the bodies of viremic controllers. Viremic controllers are a rare group of people whose immune systems naturally control HIV replication to low levels, but who nevertheless still benefit from antiretroviral therapy. This new research adds to the body of knowledge that is needed to develop an HIV cure.

Read More »
Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below